Vasopressin: a new target for the treatment of heart failure.
暂无分享,去创建一个
C. O'connor | M. Gheorghiade | K. Adams | W. Gattis | J. H. Patterson | Craig R. Lee | M. Watkins | C. O’Connor | J. Patterson
[1] K. Kikuchi,et al. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor , 1999, Molecular and Cellular Biochemistry.
[2] J. Ouyang,et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination , 2002 .
[3] M. Gheorghiade,et al. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients , 2002 .
[4] J. Ghali,et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .
[5] J. Frøkiaer,et al. Physiology and pathophysiology of renal aquaporins. , 1999, Journal of the American Society of Nephrology : JASN.
[6] D. Nisato,et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. , 2000, The Journal of pharmacology and experimental therapeutics.
[7] K. Kikuchi,et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.
[8] Y. Yamamura,et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.
[9] M. Burnier,et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects , 1999, European Journal of Clinical Pharmacology.
[10] W. Abraham,et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. , 1999, Journal of the American Society of Nephrology : JASN.
[11] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[12] K. Honda,et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. , 1999, European journal of pharmacology.
[13] L. Burrell,et al. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. , 1999, The American journal of physiology.
[14] Marvin A. Konstam,et al. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.
[15] T. Iijima,et al. On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. , 1999, Japanese journal of pharmacology.
[16] T Yamashita,et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.
[17] C. Johnston,et al. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. , 1998, American journal of physiology. Heart and circulatory physiology.
[18] J. Tsukada,et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. , 1998, Cardiovascular research.
[19] J. Taylor,et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. , 1998, Advances in experimental medicine and biology.
[20] R. Schrier,et al. Recent advances in the understanding of water metabolism in heart failure. , 1998, Advances in experimental medicine and biology.
[21] M. Takanashi,et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.
[22] R. Schrier,et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.
[23] T. Takenaka,et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. , 1997, European journal of pharmacology.
[24] C. S. Gal,et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. , 1996, The Journal of clinical investigation.
[25] L. Goldman,et al. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. , 1996, Archives of internal medicine.
[26] Y. Yamamura,et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. , 1995, The Journal of pharmacology and experimental therapeutics.
[27] T. Saruta,et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. , 1994, The American journal of physiology.
[28] T. Sugimoto,et al. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. , 1994, The Journal of biological chemistry.
[29] M. Thibonnier,et al. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. , 1994, The Journal of biological chemistry.
[30] P. Meda,et al. [Ca2+]i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. , 1994, The American journal of physiology.
[31] K. Yoshinaga,et al. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. , 1992, The American journal of physiology.
[32] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[33] B. Walker,et al. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. , 1988, The American journal of physiology.
[34] S. Goldsmith,et al. Vasopressin as vasopressor. , 1987, The American journal of medicine.
[35] J. Cohn,et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. , 1986, Journal of the American College of Cardiology.
[36] G. Francis,et al. Arginine vasopressin and the renal response to water loading in congestive heart failure. , 1986, The American journal of cardiology.
[37] T. Ryan,et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. , 1986, Journal of the American College of Cardiology.
[38] A. Cowley,et al. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. , 1986, The Journal of clinical investigation.
[39] K. Yoshinaga,et al. Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system. , 1986, Neuroendocrinology.
[40] J. Goy,et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. , 1985, The American journal of cardiology.
[41] E. Kirk,et al. Effects of vasopressin on the coronary circulation: reserve and regulation during ischemia. , 1985, The American journal of physiology.
[42] J. Cohn,et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.
[43] M. Faure,et al. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. , 1983, The American journal of physiology.
[44] T. Berl,et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.
[45] A. Guyton,et al. Textbook of Medical Physiology , 1961 .